Analysis of Elemental Impurities in Synthetic Oligonucleotides by ICP-MS In compliance with USP <232>/<233> and ICH Q3D(R2)/Q2(R1)

Application Note Biopharma Analysis of Elemental Impurities in Synthetic Oligonucleotides by ICP-MS Development and testing of an efficient Agilent 7850 ICP-MS method in compliance with USP <232>/<233> and ICH Q3D(R2)/Q2(R1) Authors Introduction Bian Yulan and Li Shuping Synthetic oligonucleotides are…

Application Note BioPharma Analysis of Elemental Impurities in GLP-1 Receptor Agonist Oral Tablets by ICP-MS Evaluation of an Agilent 7850 ICP-MS method compliant with USP <232>/<233> and ICH Q3D(R2)/ Q2(R2) Authors Bian Yulan and Li Shuping, Agilent Technologies, Inc. Introduction…

Application Note Pharmaceuticals Validating performance of an Agilent ICP‑MS for USP <232>/<233> & ICH Q3D(R2)/Q2(R1) Reducing the time and expense of ICP-MS method development and system validation for measuring elemental impurities in pharmaceuticals Authors Lindsey Whitecotton, Ed McCurdy, Craig Jones…

Application Note Pharma & Biopharma Analysis of Artificial Tear Eye Drops For Elemental Impurities Using an ICP-MS and USP <232>/<233> and ICH Q3D(R2)/Q2(R1) protocols. Authors Jennifer Sanderson and Lindsey Whitecotton Agilent Technologies, Inc. Introduction As pharmaceutical products are released to…